Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Cor.../ US4579852082 /
IART
|
17/05/2024 22:00:00
|
Diferencia
+0.0500
|
Volumen |
Bid22:48:12 |
Ask22:48:12 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
27.5400USD
|
+0.18%
|
835,428
Volumen de negocios: 15.07 millones |
26.9800Volumen de oferta: 400 |
41.8500Tamaño/ Volumen/ Formato de Ask: 100 |
2.17 mil millonesUSD |
- |
32.40 |
Descripción de negocio
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies.
Consejo de gestión & Consejo de supervisión
| CEO |
| Jan De Witte |
| Consejo de gestión |
| Carrie Anderson, Andrea Caruso, Dr. Kenneth Burhop, Eric Schwartz, Glenn G. Coleman, Judith E. O'Grady, Lisa Evoli, Michael McBreen, Robert T. Davis Jr., Sravan K. Emany, Steve Leonard, Susan Krause, William Compton |
| Consejo de supervisión |
| Dr. Stuart M. Essig, Barbara B. Hill, Christian S. Schade, Dr. Donald E. Morel, Jr., Dr. Keith Bradley, Peter J. Arduini, Raymond G. Murphy, Rhonda Germany Ballintyn, Shaundra D. Clay |
Datos de la empresa
| Nombre: |
Integra LifeSciences Holdings Corp. |
| Dirección: |
1100 Campus Road,Plainsboro, New Jersey 08540, USA |
| Teléfono: |
+1-609-275-0500 |
| Fax: |
+1-609-275-5363 |
| E-mail: |
custsvcnj@integralife.com
|
| Internet: |
www.integralife.com/ |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
Biotechnology |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
38.60% |
| Fecha de OPI: |
- |
Relación con inversores
| Nombre: |
Michael Beaulieu |
| IR teléfono: |
+1-609-936-2268 |
| IR-fax: |
- |
| IR e-mail: |
ir@integralife.com
|
Accionistas mayoritarios
| Freefloat |
|
38.60% |
| Tru St Partnership LP and Provco Leasing |
|
11.70% |
| Wellington Management Group LLP |
|
11.40% |
| Capital Research & Management Co. |
|
9.80% |
| The Vanguard Group |
|
7.70% |
| Champlain Investment Partners, LLC |
|
7.70% |
| BlackRock, Inc. |
|
7.60% |
| Janus Henderson Group plc 201 |
|
5.50% |
